Investment and M&A transaction comps
Supplement Brand Investment & M&A Transaction Comps
Supplements, vitamins, sports nutrition, wellness and functional nutrition brand transactions.
68
Reviewed transactions
43
With price data
3.6x
Median EV or valuation / revenue
17.4x
Median EV or valuation / EBITDA
| Year | Transactions | Priced | Median EV or valuation / revenue | Median EV or valuation / EBITDA |
|---|---|---|---|---|
| 2026 | 15 | 9 | 3.7x | - |
| 2024 | 3 | 3 | 5.5x | 15.0x |
| 2023 | 6 | 4 | 3.3x | 21.2x |
| 2022 | 6 | 2 | 1.8x | 22.0x |
| 2021 | 5 | 3 | 3.1x | 11.4x |
| 2020 | 8 | 6 | 5.0x | 15.7x |
| 2018 | 5 | 4 | 5.6x | 17.6x |
| 2017 | 6 | 4 | 3.6x | 19.0x |
Sortable transaction comps
Supplements transaction table
Rows with reported value
15 / 18
Acquisition EV, USD
USD 42B
Investment EV, USD
-
Median EV / revenue
3.6x
Select up to 12 rows across filters and pages, then share or export the set.
Selected comparison set
Saved in this browser only. Nothing is written to FundComb data.
Choose transactions from the table to build a quick comparison set.
18 shown of 68 matching transactions. Click any transaction row for more detail.
Values are 100% enterprise values. Multiples divide EV by full-company revenue or EBITDA. Reported prices are assumed to be EV; explicit partial-stake prices are grossed up as estimates. Amounts paid are tracked separately.
| Select for comparison | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer Consumer Healthcare Control (68%) | 2018-12-19 | GlaxoSmithKline (GSK-Pfizer consumer joint venture) | Undisclosed | Undisclosed | - | - | United States & Global | Estimated 1 source | ||
| GSK Consumer Healthcare India (Horlicks) Control (100%) | 2018-12-03 | Hindustan Unilever and Unilever | EUR 5.3B Consideration | 5,999 | 9.6x | - | India, Bangladesh & Asian Markets | Confirmed 1 source | ||
| Probiotics International Control | 2018-07-02 | ADM | USD 243M Consideration | 243 | 5.6x | 21.2x | United Kingdom | Estimated 2 sources | ||
| Nutranext Control | 2018-03-12 | Clorox | USD 700M Consideration | 700 | 3.5x | 14.0x | - | Estimated 1 source | ||
| Life-Space Group Control (100%) | 2018-01-31 | BY-HEALTH Co., Ltd. | AUD 670M Enterprise Value | 543 | - | - | Australia | Estimated 1 source | ||
| BioCare Copenhagen Control (20%) | 2017-12-22 | DSM | Undisclosed Undisclosed | Undisclosed | - | - | Denmark | Confirmed 1 source | ||
| Atrium Innovations Control | 2017-12-05 | Nestlé | USD 2.3B Consideration | 2,300 | 3.3x | 19.0x | - | Confirmed 1 source | ||
| Ganeden Control | 2017-10-11 | Kerry Group | Undisclosed | Undisclosed | 6.0x | 20.0x | - | Confirmed 1 source | ||
| Chicago Bar Company LLC (RXBAR) Control | 2017-10-06 | Kellogg Company | USD 600M Enterprise Value | 600 | 5.0x | 19.5x | United States | Confirmed 4 sources | ||
| Nutraceutical Control | 2017-05-22 | HGGC | USD 446M Enterprise Value | 446 | 1.8x | 9.9x | - | Confirmed 2 sources | ||
| Viviscal Control | 2017-01-20 | Church & Dwight | EUR 150M Consideration | 159 | 3.6x | 17.8x | - | Confirmed 2 sources | ||
| Vitaco Control | 2016-08-01 | Primavera Capital | AUD 345M Enterprise Value | 261 | 1.5x | 14.7x | Australia/New Zealand | Confirmed 1 source | ||
| Nutraceutix assets Control (100%) | 2016-06-06 | Probi AB | USD 105M Enterprise Value | 105 | 3.1x | 13.1x | United States | Confirmed 1 source | ||
| Swisse Control (83%) | 2015-09-17 | Biostime | AUD 1.7B Enterprise Value | 1,197 | 3.6x | 10.2x | Australia | Confirmed 3 sources | ||
| Atrium Innovations Inc. Control | 2013-11-29 | Permira Advisers Ltd. | USD 1.0B Enterprise Value | 1,036 | - | 10.8x | Canada | Estimated 3 sources | ||
| Schiff Nutrition Control | 2012-11-22 | Reckitt Benckiser | USD 1.4B Enterprise Value | 1,400 | 4.2x | 19.1x | - | Confirmed 3 sources | ||
| Avid Health, Inc. Control | 2012-08-20 | Church & Dwight Co., Inc. | USD 650M Enterprise Value | 650 | 2.8x | 11.2x | - | Estimated 5 sources | ||
| DuPont Nutrition & Biosciences Control | 2005-07-01 | International Flavors & Fragrances (IFF) | USD 26B Consideration | 26,200 | 4.3x | 18.9x | United States | Estimated 2 sources |
FundComb transaction comps are informational only. Prices are shown as estimated enterprise value where available, with USD used as the default sorting currency; revenue and EBITDA multiples are shown where available. Values may be estimated, rumored, incomplete or derived from public information and should not be relied upon as financial, investment or valuation advice.